INDIVIDUAL ARTICLE: Interleukin-31 in Atopic Dermatitis and Prurigo Nodularis: Pathophysiology, Neuroimmune Mechanisms, and Clinical Efficacy of Nemolizumab
Journal of Drugs in Dermatology · 2026
DOI: 10.36849/jdd.015471 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Drugs in Dermatology, 2026. Verfasst von Naiem T Issa und 3 weiteren Autor:innen. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Prurigo, Interleukins, Antibodies, Monoclonal, Humanized.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Issa, N. T., Kwatra, S., Shahbaz, A., & Kircik, L. (2026). INDIVIDUAL ARTICLE: Interleukin-31 in Atopic Dermatitis and Prurigo Nodularis: Pathophysiology, Neuroimmune Mechanisms, and Clinical Efficacy of Nemolizumab. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.015471
Vancouver
Issa NT, Kwatra S, Shahbaz A, Kircik L. INDIVIDUAL ARTICLE: Interleukin-31 in Atopic Dermatitis and Prurigo Nodularis: Pathophysiology, Neuroimmune Mechanisms, and Clinical Efficacy of Nemolizumab. Journal of Drugs in Dermatology. 2026. doi:10.36849/jdd.015471
BibTeX
@article{Issa2026,
author = {Issa, Naiem T and Kwatra, Shawn and Shahbaz, Ali and Kircik, Leon},
title = {INDIVIDUAL ARTICLE: Interleukin-31 in Atopic Dermatitis and Prurigo Nodularis: Pathophysiology, Neuroimmune Mechanisms, and Clinical Efficacy of Nemolizumab},
journal = {Journal of Drugs in Dermatology},
year = {2026},
doi = {10.36849/jdd.015471}
}
EUVIMED